Press release
SOLIRIS by AstraZeneca expected to drive market size of Generalized Myasthenia Gravis
Are you interested in finding out the projected market size of SOLIRIS in 2032? SOLIRIS Market Forecast
https://www.delveinsight.com/report-store/soliris-gmg-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The SOLIRIS Market Report offers projected sales forecasts for SOLIRIS for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
AstraZeneca's SOLIRIS is serving as a beacon of hope for the patients suffering from the Generalized Myasthenia Gravis.
What is SOLIRIS Prescribed for?
Soliris (eculizumab) has received approval in the European Union (EU) for extended application, encompassing the treatment of refractory generalized myasthenia gravis (gMG) in children and adolescents aged six to 17 years who test positive for anti-acetylcholine receptor (AChR) antibodies (Ab+). This marks the inaugural approval of a targeted therapy specifically designated for treating pediatric patients afflicted with the condition in the EU.
The report extensively covers the details and developments related to SOLIRIS, capturing important highlights on developmental pipeline, regulatory status and special designations of SOLIRIS, route of administration, safety and efficacy details.
SOLIRIS Market Assessment
This report provides a detailed market assessment of SOLIRIS for Generalized Myasthenia Gravis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.
SOLIRIS Clinical Assessment
The report provides the clinical trials information of SOLIRIS for Generalized Myasthenia Gravis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against SOLIRIS? SOLIRIS Drugs Insights
https://www.delveinsight.com/sample-request/soliris-gmg-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
SOLIRIS Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the SOLIRIS.
SOLIRIS Market Size in the US
A dedicated section of the report focuses on the expected market size of SOLIRIS for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of SOLIRIS:
• The report contains forecasted sales of SOLIRIS for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Generalized Myasthenia Gravis.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for SOLIRIS in Generalized Myasthenia Gravis.
Stay ahead in competition by leveraging insights on SOLIRIS market Report: Download SOLIRIS Market Report
https://www.delveinsight.com/sample-request/soliris-gmg-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Why you should buy SOLIRIS Market Report:
• The report provides future market assessments for SOLIRIS for Generalized Myasthenia Gravis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading SOLIRIS for Generalized Myasthenia Gravis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SOLIRIS
• Discover the competitive landscape of SOLIRIS through 7MM
• Get a Thorough Analysis of the SOLIRIS Development pipeline, Safety & Efficacy of the SOLIRIS, and ROA
• Thorough SOLIRIS market forecast will help understand how drug is competing with other emerging SOLIRIS
• Get analysis of the SOLIRIS clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Generalized Myasthenia Gravis Pipeline https://www.delveinsight.com/report-store/generalized-myasthenia-gravis-gmg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Generalized Myasthenia Gravis Pipeline Insight, 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Generalized Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key Generalized Myasthenia Gravis companies in the market include - Biocon, Cartesian Therapeutics, UCB, Momenta Pharmaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Top Services Offered By DelveInsight:
Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential
Latest Reports Offered By DelveInsight:
Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SOLIRIS by AstraZeneca expected to drive market size of Generalized Myasthenia Gravis here
News-ID: 3452631 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for SOLIRIS
Global Soliris Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
The Soliris Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Soliris Market Size and Projected Growth Rate?
In recent times, the Soliris market has experienced significant growth. The market, which stood at $1,880.37 million in 2024, is anticipated to increase to $2,030.44 million…
Future Outlook of the Soliris Intravenous Market: Soliris Intravenous Trends and …
The global Soliris Intravenous Market was valued at approximately USD 3.5 billion in 2024 and is projected to reach around USD 6.8 billion by 2033, growing at a compound annual growth rate (CAGR) of about 7.5% from 2025 to 2033.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/soliris-intravenous-market
Soliris Intravenous Market Overview:
The Soliris Intravenous Market is experiencing steady growth driven by the increasing prevalence of rare and chronic diseases such as…
Soliris Drug Market: An In-Depth Analysis
The market size for Soliris (eculizumab) was estimated at approximately USD 4.2 billion in 2023 and is projected to reach around USD 9.7 billion by 2032, indicating a compound annual growth rate (CAGR) of 9.7% from 2024 to 2032.
Soliris Drug Market Overview
The Soliris (eculizumab) drug market plays a crucial role in the treatment of rare and life-threatening diseases, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS),…
Growing Prevalence Of Rare Blood Disorders To Drive Soliris Market Expansion: Ma …
How Will the Soliris Market Grow, and What Is the Projected Market Size?
The market size of Soliris has experienced significant growth in the past few years. Its expansion from $1,880.37 million in 2024 to $2,030.44 million in 2025 represents a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this growth during the historic period include regulatory approvals, increased awareness of rare diseases, a rising demand for complement inhibition,…
Soliris Market Size, Growing Demand to 2033 Alexion
Soliris (eculizumab) is a groundbreaking monoclonal antibody used to treat rare, life-threatening diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). It works by inhibiting the complement system, a part of the immune response that can attack healthy cells when overactivated. Approved by the FDA in 2007, Soliris was one of the most expensive drugs globally, reflecting its role in addressing ultra-rare conditions.…
Global Soliris Intravenous Market, Size, Share, Analysis Report & Forecast to 20 …
The global Soliris intravenous market is expected to grow at a significant CAGR during the forecast period (2021-2027). Eculizumab is a medicine that is used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and neuromyelitis optica. It is offered under the trade names Soliris and others. It appears to lower both the breakdown of red blood cells and the requirement for blood transfusions in patients with PNH,…
